An AllTrials project

NCT04569747: An ongoing trial by Dana-Farber Cancer Institute

This trial is ongoing. It must report results 2 years from now.

Full data

Full entry on ClinicalTrials.gov NCT04569747
Title 20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Jan. 11, 2021
Completion date Sept. 1, 2026
Required reporting date Sept. 1, 2027, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Aug. 26, 2025
Days late None